Castleman Disease Trial, Recruiting NCT03717844 Sponsor: UNC Lineberger Comprehensive Cancer Center Condition: Castleman Disease
Back to Castleman Disease

Castleman Disease Trial, Recruiting

NCT03717844
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have an appointment or are staying as a patient at UNC Cancer Hospitals, an affiliated clinic, or one of the participating locations for the assessment or treatment of a plasma cell disorder.
  • You have been diagnosed with a plasma cell disorder, which means a condition where abnormal proteins or abnormal plasma cells are found in your body — examples include MGUS, smoldering myeloma, multiple myeloma, amyloidosis, POEMS syndrome, and similar conditions.
  • You are 18 years old or older.
  • You are willing to take part in the study and agree to complete surveys or assessments at the start of the study and at later follow-up points.
  • You are able to read and speak English.

Who may not be able to join:

  • You have physical health problems, mental health conditions, or behavioral issues that your doctor feels would make it too difficult for you to take part in the study successfully.

Important note on eligibility checks:

  • No special scans or blood tests are needed just to find out if you qualify for this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sascha Tuchman, MD, UNC Lineberger Comprehensive Cancer Center

Phone: (919) 966-4432

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
UNC Lineberger Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
9 February 2018
Est. completion
1 February 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Creation of a Registry of Plasma Cell Disorder (PCD) patients; Completion of baseline and longitudinal assessments in PCD patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov